Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B

Table 1 Characteristics of patients included in this study

	ALT≥2ULN	ALT < 2ULN
Number of patients	78	59
Age (SD)	35.2 (7)	38.7 (7.4)
Gender
Male	70.5%	69.5%
Female	29.5%	30.5%
Stage of fibrosis (%)
F0 + F1	33 (42.3)	24 (40.7)
F2	26 (33.3)	20 (33.9)
F3	13 (16.7)	9 (15.2)
F4	6 (7.7)	6 (10.1)
Significant fibrosis (≥ F2)	45 (57.3)	35 (59.3)
APRI1(SD)
F0 + F1	0.55 (0.82)	0.48 (0.33)
F2	1.44 (1.79)	1.21 (1.57)
F3	1.98 (2.34)	1.69 (1.62)
F4	2.11 (1.81)	1.97 (1.73)
Significant fibrosis (≥ F2)	1.84 (1.38)	1.62 (1.45)
HA (SD)
F0 + F1	131.3 (82.7)	129.9 (79.8)
F2	199.3 (158.2)	190.5 (149.9)
F3	285.3 (188.6)	285.7 (187.3)
F4	324.9 (212.6)	333.3 (224.1)
Significant fibrosis (≥ F2)	269.8 (214.1)	268.9 (187.1)

¹APRI: (AST/ULN) × 100/PLT.

Table 2 Sensitivity, specificity, PPV, and NPV of APRI > 1.5 in combination with different HA cut-off points for the detection of liver fibrosis (stages 2-4) in CHB patients

	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	+LR	-LR
APRI ≥ 1.5	44.7	84.3	41.3	84.7	2.80	0.66
+HA ≥ 150	46.6	95.6	88.6	89.5	10.6	0.56
+HA ≥ 200	46.8	97.8	90.2	89.9	21.3	0.54
+HA ≥ 250	47.3	98.7	93.2	90.2	36.4	0.53
+HA ≥ 300	45.3	98.9	93.7	91.3	41.2	0.55

Table 3 Sensitivity, specificity, PPV, and NPV of APRI ≤ 1.5 in combination with different HA cut-off points for the detection of liver fibrosis (stages 0-1) in CHB patients

	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	+LR	-LR
APRI < 1. 5	35.3	81.6	41.3	82.2	1.9	0.79
+HA < 300	45.7	86.2	44.6	83.1	3.3	0.63
+HA < 250	42.8	83.2	42.8	81.3	2.5	0.69
+HA < 200	38.5	80.8	40.8	80.3	2.0	0.76
+HA < 150	31.7	78.8	37.1	77.7	1.5	0.87